Iberdomide decreases B cells and plasmacytoid dendritic cells, increases regulatory T cells and IL-2, and has enhanced clinical efficacy in active systemic lupus erythematosus patients with High Aiolos or the IFN gene expression signature. [AUT.] PETER LIPSKY, RONALD VAN VOLLENHOVEN, THOMAS DÖRNER, VICTORIA WERTH, JOAN MERRILL, RICHARD FURIE, MILAN PETRONIJEVIC, BENITO VELASCO ZAMORA, MARIA MAJDAN, FEDRA IRAZOQUE-PALAZUELOS, ROBERT TERBRUEGGEN, NIKOLAY DELEV, MICHAEL WEISWASSER, SHIMON KORISH, NATALIYA AGAFONOVA, MARK STERN, SARAH HERSEY, YING YE, ALLISON GAUDY, ZHAOHUI LIU, SHAOJUN TANG, PETER SCHAFER. W: ACR Convergence 2020. [B. m.] 5-9 November 2020 [online]. [Streszcz.] [art. nr] 0851, [b. pag.], [przeglądany 18 listopada 2020]. Dostępny w: https://acrabstracts.org/abstract/iberdomide-decreases-b-cells-and-plasmacytoid-dendritic-cells-increases-regulatory-t-cells-and-il-2-and-has-enhanced-clinical-efficacy-in-active-systemic-lupus-erythematosus-patients-with-high-aiolo/.